Overview
JBIO market data
Price History
JBIO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.59 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.67 – $28.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.5B · P/B 2.13.
Company News
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $47Benzinga · Aug 11, 2026, 1:40 PM
8-K filing — Jade Biosciences, Inc. (JBIO)SEC EDGAR · Aug 10, 2026, 11:13 AM
Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) EstimateBenzinga · Aug 10, 2026, 11:08 AM
Jade Biosciences Enters Exclusive Worldwide License Agreement With Paragon Therapeutics; To Pay Up To $22M In Milestone Payments To Paragon; To Pay Paragon Low To Mid-Single-Digit Percentage Royalties On Net Sales Of Licensed Products; Paragon Barred From New Campaigns Targeting Licensed Target For At Least Five YearsBenzinga · Jul 1, 2026, 9:25 PM
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of DirectorsGlobenewswire Inc · Jun 26, 2026, 11:15 AM
UBS Initiates Coverage On Jade Biosciences with Buy Rating, Announces Price Target of $45Benzinga · Jun 15, 2026, 1:00 PM
Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall As House Challenges Trump's Military Authority— Broadcom, CrowdStrike In Focus (UPDATED)Benzinga · Jun 4, 2026, 1:15 PM
Jade Biosciences Reveals Proposed Underwritten Public Offering; No Size DisclosedBenzinga · Jun 3, 2026, 8:10 PM
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $45Benzinga · Jun 2, 2026, 1:13 PM
Why Is Jade Biosciences Stock Trading Lower On Monday?Benzinga · Jun 1, 2026, 5:59 PM